InflaRx Focuses on Terminal Complement Inhibition with Izicopan and Vilobelimab at Oppenheimer Conference

InflaRx, a biotech company, has streamlined its corporate strategy to focus on izicopan, an oral C5a receptor 1 inhibitor, for inflammatory and immunology indications. The company aims to advance vilobelimab, an intravenous anti-C5a antibody, in acute respiratory distress syndrome. InflaRx targets the terminal complement pathway, specifically C5a/C5aR signaling, which can contribute to tissue damage during inflammatory flares. Izicopan is believed to be differentiated from avacopan, a marketed C5aR inhibitor, through higher exposure, target engagement, speed to therapeutic levels, drug-drug interaction, and formulation/dosing convenience.